Abstract
We present our experience with AVflo™, a nanofiber, electrospun, self-sealing, early-access graft for hemodialysis (HD).
Objective
Evaluating the safety and efficacy of the AVflo™ graft in terms of patency and complications (early and late) over 2 years.
Materials and methods
Twelve end-stage renal disease (ESRD) patients (age: mean 68.5 ± 10 years) were followed up for a mean period of 946 ± 570 days after receiving an implantation of the graft for HD. The grafts were implanted at the lower arm (loop configuration), upper arm (straight configuration) and the thigh (loop configuration). First dialysis was performed at day 7 (3-21) following implantation.
Results and discussion
After a mean follow up of 24 months, the primary patency was 56% and the secondary patency was 82%. In this group, AVflo™ shows similar if not superior efficacy and safety to that of available grafts in terms of safety, complications, and long-term patency.
Get full access to this article
View all access options for this article.